According to our latest study on "Metastatic Cancer Drug Market Forecast to 2028 – COVID-19 Impact and Global Analysis– by Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous, Intramuscular, Oral, and Others), Drug Class (HER2 Inhibitor, Immune Checkpoint Inhibitor, PARP Inhibitor, Kinase Inhibitor, and Others), Product (Branded and Generic & Biosimilar), End User (Hospital, Specialty Clinic, and Others)," the metastatic cancer drug market size is expected to grow from US$ 51,157.97 million in 2021 to US$ 68,349.54 million by 2028. It is estimated to grow at a CAGR of 4.2% from 2021 to 2028.
The report highlights the key factors driving the market and prominent players with their developments. The metastatic cancer drugs market growth is attributed to the increasing prevalence of cancer and government initiatives to support drug developments for cancer treatment. However, the high cost of oncology drugs is expected to hamper metastatic cancer drug market growth.
The COVID-19 outbreak has had a significant impact on operations in a variety of industries. The pandemic has impacted cancer patients in two ways. It had a disproportional effect on mortality in cancer patients. Patients with cancer had an increased risk of severe outcomes from coronavirus infection. Cancer and cancer-related treatments commonly cause immunosuppression, making cancer patients more susceptible to severe coronavirus disease. Most cancer patients were over 65 years old (geriatric/elderly group) and had one or more comorbidities. The COVID-19 pandemic has also resulted in many hurdles to accessing cancer care. These obstacles were in addition to existing access delays due to pricing and reimbursement processes, national reimbursement criteria, and the variation in readiness of health systems to integrate new therapies in clinical practice. Outcomes for cancer patients are likely to be negatively affected if the usual standard of care is delayed.
During the pandemic, patients were less likely to visit the hospital for their cancer care, and doctors had to make new trade-offs between the risks and benefits of cancer treatment. Also, the availability of healthcare personnel has been limited. Delays in cancer diagnosis, treatment, and follow-up have led to more patients receiving their diagnoses at a more advanced stage of their disease. It has been reported that a treatment delay of 4 weeks is associated with a 6-13% increase in the risk of death. Additionally, it was estimated that breast and colon cancer deaths are expected to increase by 8% to 17%, respectively, up to 5 years after diagnosis. Many professional societies have published recommendations to help manage patients with cancer during the current pandemic.
Additionally, the delayed clinical trials and drug approvals also hampered metastatic can drug market growth. As the pandemic is at its end stage, the FDA has increased its efforts to support people's health and has imposed several guidelines for hospitals and medical device companies. Various companies also enhanced their research and development activities in searching for new molecules that will effectively treat the rising burden of cancer disease.
Based on cancer type, the metastatic cancer drug market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. The breast cancer segment accounted for the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. As per the American Society of Clinical Oncology, 287,850 women in the US are expected to be diagnosed with invasive breast cancer, and 51,400 women are likely to be diagnosed with non-invasive (in situ) breast cancer by the end of 2022. 6% of women have metastatic breast cancer when they are first diagnosed in the country. Symptoms are visible in the early stages of breast cancer, but abnormality can be seen on a mammogram only.
The most common symptoms observed in the breast cancer patient include breast pain, lump, swelling, and discharge, peeling, scaling, flaking of the breast skin, change in shape and size of breast lump, swelling in under arm area, and others.
Breast cancer is bifurcated into two types: invasive and non-invasive breast cancer. Invasive breast cancer starts from breast ducts or glands and spreads to other breast tissues. However, non-invasive cancer does not spread from original tissues. Moreover, inflammatory breast cancer (IBC) and triple-negative breast cancer are some other types of rare breast cancer that are very aggressive. Breast cancer can be diagnosed by mammogram, ultrasound, breast tissue biopsy, and treatment options include surgery, radiation therapy, chemotherapy, hormone therapy, and additional medications. The breast cancer survival rates depend upon the stage of cancer during diagnosis. The early diagnosis has high survival rates, and as the treatment evolves, the survival rates are improved significantly. According to the American Society of Clinical Oncology, in 2022, the 5-year survival rate for women with metastatic breast cancer is 29%. The 5-year survival rate for men with metastatic breast cancer is 22%.
AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., Novartis AG, ASTRAZENECA PLC., Eli Lilly and Company, MERCK KGaA, and Pfizer Inc. (Arena Pharmaceutical GmbH) are among the leading companies in the metastatic cancer drug market.
Metastatic Cancer Drug Market, by Region, 2021 (%)
Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous, Intramuscular, Oral, and Others), Drug Class (HER2 Inhibitor, Immune Checkpoint Inhibitor, PARP Inhibitor, Kinase Inhibitor, and Others), Product (Branded and Generic & Biosimilar), and End User (Hospital, Specialty Clinic, and Others)
Metastatic Cancer Drug Market Size, Share & Growth by 2028
Download Free Sample
The report segments the metastatic cancer drug market as follows:
The metastatic cancer drug market is analyzed on the basis of cancer type, route of administration, drug class, product, end user, and geography. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is segmented into intravenous, intramuscular, oral, and others. Based on drug class, the metastatic cancer drug market is segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. Based on product, the metastatic cancer drug market is bifurcated into branded products and generics and biosimilars. Based on end user, the metastatic cancer drug market is segmented into hospitals, specialty clinics, and others.
By geography, the metastatic cancer drug market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com